logo
Plus   Neg
Share
Email

Genentech: Gazyva Meets Endpoints In Phase II Lupus Nephritis Trial

Genentech, a member of the Roche Group (ROG.SW,RO.SW), said a Phase II clinical trial investigating Gazyva for adults with proliferative lupus nephritis met its primary endpoint. Gazyva, in combination with standard of care, demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year. Gazyva also met key secondary endpoints in the study.

Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found only on certain types of B-cells. In the U.S., Gazyva is part of an association between Genentech and Biogen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a new $600 million investment for the expansion of Mayes County data center. The tech giant had started the data center in 2007 and expanded three times already. The new investment will add 100 jobs to Pryor community, Google CEO Sundar Pichai said during the announcement. In... King Arthur Flour, Inc. voluntarily recalled certain lots of 5 lb. Unbleached All-Purpose Flour due to the potential presence of Escherichia coli bacteria (E. coli), The U.S. Food and Drug Administration (FDA) stated. The company announced it is recalling 14,218 cases of the potentially affected lots that were distributed through retailers and distributors nationwide. Burger King has launched a new Upside Down Whopper in celebration of the third season of Netflix series "Stranger Things." The hamburger chain, in partnership with Netflix, announced it will start selling an Upside Down Whopper sandwich, which is just a regular Whopper served upside down, from June...
Follow RTT